GenapSys launches sequencer in Asia, lands new funding
GenapSys has launched its gene sequencer in the Asia-Pacific region and garnered $75 million in financing to support its international expansion. Read More
GenapSys has launched its gene sequencer in the Asia-Pacific region and garnered $75 million in financing to support its international expansion. Read More
Arbor offers NGS coronavirus panel to researchers for free
Arbor Biosciences announced on February 12 that it will release its myBaits Expert hybridization-based panel for detecting infection with the 2019 novel coronavirus (2019-nCoV). The next-generation sequencing (NGS) panel will be offered free of charge to global researchers helping to identify the source organism and evolution of the virus. Read More
Arbor Biosciences announced on February 12 that it will release its myBaits Expert hybridization-based panel for detecting infection with the 2019 novel coronavirus (2019-nCoV). The next-generation sequencing (NGS) panel will be offered free of charge to global researchers helping to identify the source organism and evolution of the virus. Read More
WHO officially names coronavirus disease COVID-19
The World Health Organization (WHO) on February 11 announced an official designation for the disease caused by the novel coronavirus (2019-nCoV), naming the condition COVID-19. Read More
The World Health Organization (WHO) on February 11 announced an official designation for the disease caused by the novel coronavirus (2019-nCoV), naming the condition COVID-19. Read More
Opposition fails for key CRISPR patent in Europe
ERS Genomics announced on February 10 that the European Patent Office has upheld an important CRISPR patent, rejecting opposition filed by anonymous parties. Read More
ERS Genomics announced on February 10 that the European Patent Office has upheld an important CRISPR patent, rejecting opposition filed by anonymous parties. Read More
Bosc named president of Women in Bio
Jessica Bosc, director of business development and licensing at Selexis, has been named president of Women in Bio, following a one-year term as president-elect. Read More
Jessica Bosc, director of business development and licensing at Selexis, has been named president of Women in Bio, following a one-year term as president-elect. Read More
ERS Genomics licenses CRISPR tech to Aelian
ERS Genomics announced on February 11 that it has entered an agreement to license its portfolio of CRISPR technology to Aelian Biotechnology. Read More
ERS Genomics announced on February 11 that it has entered an agreement to license its portfolio of CRISPR technology to Aelian Biotechnology. Read More
MilliporeSigma unveils BrightLab for research scientists
MilliporeSigma has introduced BrightLab, a cloud-based inventory management and instrument connectivity platform for research scientists. Read More
MilliporeSigma has introduced BrightLab, a cloud-based inventory management and instrument connectivity platform for research scientists. Read More
Thermo Scientific launches reagent dispensers
Thermo Scientific has launched a new family of high-precision digital reagent dispensers that are designed to facilitate the miniaturization of assays and improve throughput for scientists across multiple applications. Read More
Thermo Scientific has launched a new family of high-precision digital reagent dispensers that are designed to facilitate the miniaturization of assays and improve throughput for scientists across multiple applications. Read More
Trump's 2021 budget calls for 8% NIH cut
U.S. President Donald Trump on February 10 released a proposed budget for 2021 that includes an 8% cut in funding to the U.S. National Institutes of Health (NIH), proposing a 2021 budget of $38 billion, compared with the $41.4 billion for 2020. Read More
U.S. President Donald Trump on February 10 released a proposed budget for 2021 that includes an 8% cut in funding to the U.S. National Institutes of Health (NIH), proposing a 2021 budget of $38 billion, compared with the $41.4 billion for 2020. Read More
ReForm Biologics, MilliporeSigma ink license agreement
ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications. The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use. Read More
ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications. The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
